India have kept faith with opener Prithvi Shaw while opting for Wriddhiman Saha ahead of Rishabh Pant as wicketkeeper for the opening day-night Test against Australia in Adelaide starting on Thursday (17).
Selectors also confirmed Umesh Yadav as the third seamer alongside Mohammed Shami and Jasprit Bumrah in the absence of the injured Ishant Sharma, while Ravi Ashwin won the race to be their frontline spinner ahead of Kuldeep Yadav.
The flamboyant Shaw was under pressure from another young talent -- Shubman Gill, also 21 -- to open the innings alongside Mayank Agarwal after just one decent knock in four warm-up innings.
But he will take the field for his fifth cap on Thursday while Gill continues his wait to earn a first.
"Shubman has not gotten opportunities at this level yet in Test cricket," skipper Virat Kohli said shortly before the team was announced.
"As and when he gets an opportunity, it would be interesting to see how he goes because he is a very confident young man.
"Prithvi has performed at the Test level, but he would be playing in Australia for the first time. I think it is very exciting to see his progress as well."
The dogged and experienced Cheteshwar Pujara will come in at number three, followed by Kohli in his only Test of the tour before heading home for the birth of his first child.
Vice-captain Ajinkya Rahane and Hanuma Vihari, who both scored centuries in warm-up games against Australia A, round out the middle order.
Pant, an explosive batsman who became a viral sensation on India's last tour of Australia with his banter behind the stumps, also stroked a quickfire ton against Australia A, but he was surprisingly overlooked in favour of Saha.
India won their maiden series 2-1 in Australia in 2018-19 -- including victory in Adelaide, although that game was not a day-night Test.
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.